Covid-19-Related Severe Heterogeneous Acute Respiratory Distress Syndrome: A Therapeutic Challenge

Covid-19-Related Severe Heterogeneous Acute Respiratory Distress Syndrome: A Therapeutic Challenge Publisher

Jamaati H¹ ; Fadaizadeh L² ; Khoundabi B³ ; Hashemian S¹ ; Monjazabi F⁴ ; Jahangirifard A¹ ; Beigmohammadi M⁵ ; Farzanegan B⁶ ; Shojaei S⁷ ; Tabarsi P⁸ ; Dastan F^{1, 9} ; Reza Nadji S¹⁰ ; Toutkaboni M¹¹ ; Malekmohammad M⁶ Show All Authors

Jamaati H¹
Fadaizadeh L²
Khoundabi B³
Hashemian S¹
Monjazabi F⁴
Jahangirifard A¹
Beigmohammadi M⁵
Farzanegan B⁶
Shojaei S⁷
Tabarsi P⁸
Dastan F^{1, 9}
Reza Nadji S¹⁰
Toutkaboni M¹¹
Malekmohammad M⁶
Mohamadnia A¹
Mortaz E¹²
Mirenayat M¹³
Yassari F¹⁴
Heshmatnia J¹⁴
Eslaminejad A¹
Velayati A¹⁵

Show Affiliations

1. Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Telemedicine Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Iran Helal Institute of Applied Science and Technology, Research Center for Health Mnagement in Mass Gathering, Red Crescent Society of the Islamic Republic of Iran, Tehran, Iran
4. Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5. Anaesthesiology and Intensive Care Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
6. Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
7. Department of Critical Care Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
8. Clinical Tuberculosis and Epidemiology Research Centre, National Research Institute for Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
9. Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
10. Virology Research Center, National Research Institute for Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
11. Pediatric Respiratory Diseases Research Center, National Research Institute for Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
12. Clinical Tuberculosis and Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
13. Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
14. Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
15. Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Biomedical and Biotechnology Research Journal Published:2020

Abstract

Background: A heterogeneous pattern was detected in COVID-19 severe acute respiratory distress syndrome (ARDS) patients. The aim of this study was to define special features and individualized treatment modalities for this fatal infectious disease. Methods: Thirty-six patients diagnosed as COVID-19 severe ARDS were chosen. Lung mechanics (compliance), the extravascular lung water index (EVLWI) and pulmonary vascular permeability index (PVPI), and serum concentrations of immunology markers (interleukin [IL]-1β, IL-6, IL-8, ferritin, and C-reactive protein) were measured. Accordingly, individualized treatment consisting of Actemra, hemoperfusion (HP), continuous renal replacement therapy (CRRT), and extracorporeal membrane oxygenation (ECMO) was implemented for each patient. Results: Patients were categorized according to the lung compliance: 18 in 'L type' with compliance >40 cc/cmH2O and 18 in 'H type' with compliance ≤40 cc/cmH2O. In 16 patients, standard mechanical ventilation management and antiviral therapy were unsuccessful; therefore, hemodynamic and immunity responses were evaluated. Results of transpulmonary thermodilution in L-type patients surprisingly showed EVLWI = 8.8 ± 1.3 (6.9-9.7) and PVPI = 2.4 ± 0.1 (2.2-2.6). In the H-type patients, five cases showed EVLWI = 8.7 ± 0.8 (7.5-9.8) and PVPI = 2.6 ± 0.3 (2.1-2.8) which were subclassified as 'Ha type' and five cases with EVLWI = 17.5 ± 1.9 (15.7-20.6) and PVPI = 3.9 ± 0.4 (3.5-4.5) were named 'Hb type'. By measuring immunologic markers, these two groups were subdivided into high and low marker groups. Individualized treatment resulted in 2 survivals with Actemra, 1 with HP, 2 with HP + CRRT, and 1 with ECMO. Conclusion: According to the heterogeneity of COVID-19 severe ARDS presentation, which is due to various immunologic and hemodynamic responses, a systematic approach is an important and relatively successful strategy in choosing the appropriate treatment modality. © 2020 Medknow.

Related Docs

View other Related Docs

1. Ten Challenging Questions About Sars-Cov-2 and Covid-19, Expert Review of Respiratory Medicine (2020)

2. Immunomodulatory-Based Therapy As a Potential Promising Treatment Strategy Against Severe Covid-19 Patients: A Systematic Review, International Immunopharmacology (2020)

3. Recent Findings on the Coronavirus Disease 2019 (Covid-19); Immunopathogenesis and Immunotherapeutics, International Immunopharmacology (2020)

4. Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies, International Immunopharmacology (2021)

5. Early Hemoperfusion for Cytokine Removal May Contribute to Prevention of Intubation in Patients Infected With Covid-19, Blood Purification (2021)

6. Covid-19: A Systematic Review and Update on Prevention, Diagnosis, and Treatment, MedComm (2022)

7. The Immune System and Covid-19: Friend or Foe?, Life Sciences (2020)

8. Clinical Symptoms and Types of Samples Are Critical Factors for the Molecular Diagnosis of Symptomatic Covid-19 Patients: A Systematic Literature Review, International Journal of Microbiology (2021)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (11)

Mohammadreza Salehi (5)

Style	Citing Format
MLA	Jamaati H, et al.. "Covid-19-Related Severe Heterogeneous Acute Respiratory Distress Syndrome: A Therapeutic Challenge." Biomedical and Biotechnology Research Journal, vol. 4, no. 5, 2020, pp. S75-S82.
APA	Jamaati H, Fadaizadeh L, Khoundabi B, Hashemian S, Monjazabi F, Jahangirifard A, Beigmohammadi M, Farzanegan B, Shojaei S, Tabarsi P, Dastan F, Reza Nadji S, Toutkaboni M, Malekmohammad M, Mohamadnia A, Mortaz E, Mirenayat M, Yassari F, Heshmatnia J, ... Velayati A (2020). Covid-19-Related Severe Heterogeneous Acute Respiratory Distress Syndrome: A Therapeutic Challenge. Biomedical and Biotechnology Research Journal, 4(5), S75-S82.
Chicago	Jamaati H, Fadaizadeh L, Khoundabi B, Hashemian S, Monjazabi F, Jahangirifard A, Beigmohammadi M, et al.. "Covid-19-Related Severe Heterogeneous Acute Respiratory Distress Syndrome: A Therapeutic Challenge." Biomedical and Biotechnology Research Journal 4, no. 5 (2020): S75-S82.
Harvard	Jamaati H et al. (2020) 'Covid-19-Related Severe Heterogeneous Acute Respiratory Distress Syndrome: A Therapeutic Challenge', Biomedical and Biotechnology Research Journal, 4(5), pp. S75-S82.
Vancouver	Jamaati H, Fadaizadeh L, Khoundabi B, Hashemian S, Monjazabi F, Jahangirifard A, et al.. Covid-19-Related Severe Heterogeneous Acute Respiratory Distress Syndrome: A Therapeutic Challenge. Biomedical and Biotechnology Research Journal. 2020;4(5):S75-S82.
BibTex	@article{ author = {Jamaati H and Fadaizadeh L and Khoundabi B and Hashemian S and Monjazabi F and Jahangirifard A and Beigmohammadi M and Farzanegan B and Shojaei S and Tabarsi P and Dastan F and Reza Nadji S and Toutkaboni M and Malekmohammad M and Mohamadnia A and Mortaz E and Mirenayat M and Yassari F and Heshmatnia J and Eslaminejad A and Velayati A}, title = {Covid-19-Related Severe Heterogeneous Acute Respiratory Distress Syndrome: A Therapeutic Challenge}, journal = {Biomedical and Biotechnology Research Journal}, volume = {4}, number = {5}, pages = {S75-S82}, year = {2020} }
RIS	TY - JOUR AU - Jamaati H AU - Fadaizadeh L AU - Khoundabi B AU - Hashemian S AU - Monjazabi F AU - Jahangirifard A AU - Beigmohammadi M AU - Farzanegan B AU - Shojaei S AU - Tabarsi P AU - Dastan F AU - Reza Nadji S AU - Toutkaboni M AU - Malekmohammad M AU - Mohamadnia A AU - Mortaz E AU - Mirenayat M AU - Yassari F AU - Heshmatnia J AU - Eslaminejad A AU - Velayati A TI - Covid-19-Related Severe Heterogeneous Acute Respiratory Distress Syndrome: A Therapeutic Challenge JO - Biomedical and Biotechnology Research Journal VL - 4 IS - 5 SP - S75 EP - S82 PY - 2020 ER -

Style

Citing Format

MLA

Jamaati H, et al.. "Covid-19-Related Severe Heterogeneous Acute Respiratory Distress Syndrome: A Therapeutic Challenge." Biomedical and Biotechnology Research Journal, vol. 4, no. 5, 2020, pp. S75-S82.

APA

Jamaati H, Fadaizadeh L, Khoundabi B, Hashemian S, Monjazabi F, Jahangirifard A, Beigmohammadi M, Farzanegan B, Shojaei S, Tabarsi P, Dastan F, Reza Nadji S, Toutkaboni M, Malekmohammad M, Mohamadnia A, Mortaz E, Mirenayat M, Yassari F, Heshmatnia J, ... Velayati A (2020). Covid-19-Related Severe Heterogeneous Acute Respiratory Distress Syndrome: A Therapeutic Challenge. Biomedical and Biotechnology Research Journal, 4(5), S75-S82.

Chicago

Jamaati H, Fadaizadeh L, Khoundabi B, Hashemian S, Monjazabi F, Jahangirifard A, Beigmohammadi M, et al.. "Covid-19-Related Severe Heterogeneous Acute Respiratory Distress Syndrome: A Therapeutic Challenge." Biomedical and Biotechnology Research Journal 4, no. 5 (2020): S75-S82.

Harvard

Jamaati H et al. (2020) 'Covid-19-Related Severe Heterogeneous Acute Respiratory Distress Syndrome: A Therapeutic Challenge', Biomedical and Biotechnology Research Journal, 4(5), pp. S75-S82.

Vancouver

Jamaati H, Fadaizadeh L, Khoundabi B, Hashemian S, Monjazabi F, Jahangirifard A, et al.. Covid-19-Related Severe Heterogeneous Acute Respiratory Distress Syndrome: A Therapeutic Challenge. Biomedical and Biotechnology Research Journal. 2020;4(5):S75-S82.

BibTex

@article{ author = {Jamaati H and Fadaizadeh L and Khoundabi B and Hashemian S and Monjazabi F and Jahangirifard A and Beigmohammadi M and Farzanegan B and Shojaei S and Tabarsi P and Dastan F and Reza Nadji S and Toutkaboni M and Malekmohammad M and Mohamadnia A and Mortaz E and Mirenayat M and Yassari F and Heshmatnia J and Eslaminejad A and Velayati A}, title = {Covid-19-Related Severe Heterogeneous Acute Respiratory Distress Syndrome: A Therapeutic Challenge}, journal = {Biomedical and Biotechnology Research Journal}, volume = {4}, number = {5}, pages = {S75-S82}, year = {2020} }

RIS

TY - JOUR
AU - Jamaati H
AU - Fadaizadeh L
AU - Khoundabi B
AU - Hashemian S
AU - Monjazabi F
AU - Jahangirifard A
AU - Beigmohammadi M
AU - Farzanegan B
AU - Shojaei S
AU - Tabarsi P
AU - Dastan F
AU - Reza Nadji S
AU - Toutkaboni M
AU - Malekmohammad M
AU - Mohamadnia A
AU - Mortaz E
AU - Mirenayat M
AU - Yassari F
AU - Heshmatnia J
AU - Eslaminejad A
AU - Velayati A
TI - Covid-19-Related Severe Heterogeneous Acute Respiratory Distress Syndrome: A Therapeutic Challenge
JO - Biomedical and Biotechnology Research Journal
VL - 4
IS - 5
SP - S75
EP - S82
PY - 2020
ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract